OBJECTIVES: Antiviral treatment in chronic hepatitis C (CHC) involves ribavirin, a hemolytic agent. We planned a prospective study to evaluate whether drug-induced iron perturbation is clinically relevant as it relates to therapeutic outcome. METHODS: Iron variables were sequentially assessed in 206 CHC patients undergoing antiviral therapy and were correlated with pretreatment iron status and histology, hemolysis, and therapeutic outcome. RESULTS: At week 1 of therapy, serum iron (SI), transferrin saturation (TS), and serum ferritin (SF) increased markedly in all patients. All iron parameters correlated with hemolysis up to week 4; this correlation was lost for SF at later time points. SF rise during treatment was inversely related to baseline SF and iron deposits in hepatic mesenchymal/Kupffer cells. Both baseline SF and mesenchymal iron significantly correlated with fibrosis at multivariate analysis (P=0.015 and 0.008, respectively). Interestingly, baseline SF, despite good specificity (89%), had low sensitivity in predicting siderosis (25%). During therapy, SI, TS, and hemolysis parameters did not correlate with sustained virological response (SVR), whereas SF rise became an independent predictor of therapeutic response: a 2.5-fold increase of SF at week 12 associated with higher likelihood of SVR (odds ratio 1.91, P=0.032). Accordingly, lack of mesenchymal iron deposits at the baseline biopsy correlated with SVR (odds ratio 3.02, P=0.043). CONCLUSIONS: In CHC, SF is a useful marker for assessing disease duration and progression before starting treatment and for predicting therapeutic response while on therapy. SF rise during antiviral therapy is largely independent of hemolysis and likely indicates activation of macrophages in response to antivirals.

Ferrara, F., Ventura, P., Vegetti, A., Guido, M., Abbati, G., Corradini, E., et al. (2009). Serum ferritin as a predictor of treatment outcome in patients with chronic hepatitis C. THE AMERICAN JOURNAL OF GASTROENTEROLOGY, 104(3), 605-616 [10.1038/ajg.2008.126].

Serum ferritin as a predictor of treatment outcome in patients with chronic hepatitis C.

Fagiuoli S;
2009

Abstract

OBJECTIVES: Antiviral treatment in chronic hepatitis C (CHC) involves ribavirin, a hemolytic agent. We planned a prospective study to evaluate whether drug-induced iron perturbation is clinically relevant as it relates to therapeutic outcome. METHODS: Iron variables were sequentially assessed in 206 CHC patients undergoing antiviral therapy and were correlated with pretreatment iron status and histology, hemolysis, and therapeutic outcome. RESULTS: At week 1 of therapy, serum iron (SI), transferrin saturation (TS), and serum ferritin (SF) increased markedly in all patients. All iron parameters correlated with hemolysis up to week 4; this correlation was lost for SF at later time points. SF rise during treatment was inversely related to baseline SF and iron deposits in hepatic mesenchymal/Kupffer cells. Both baseline SF and mesenchymal iron significantly correlated with fibrosis at multivariate analysis (P=0.015 and 0.008, respectively). Interestingly, baseline SF, despite good specificity (89%), had low sensitivity in predicting siderosis (25%). During therapy, SI, TS, and hemolysis parameters did not correlate with sustained virological response (SVR), whereas SF rise became an independent predictor of therapeutic response: a 2.5-fold increase of SF at week 12 associated with higher likelihood of SVR (odds ratio 1.91, P=0.032). Accordingly, lack of mesenchymal iron deposits at the baseline biopsy correlated with SVR (odds ratio 3.02, P=0.043). CONCLUSIONS: In CHC, SF is a useful marker for assessing disease duration and progression before starting treatment and for predicting therapeutic response while on therapy. SF rise during antiviral therapy is largely independent of hemolysis and likely indicates activation of macrophages in response to antivirals.
Articolo in rivista - Articolo scientifico
Serum ferritin; chronic hepatitis C;
English
605
616
12
Ferrara, F., Ventura, P., Vegetti, A., Guido, M., Abbati, G., Corradini, E., et al. (2009). Serum ferritin as a predictor of treatment outcome in patients with chronic hepatitis C. THE AMERICAN JOURNAL OF GASTROENTEROLOGY, 104(3), 605-616 [10.1038/ajg.2008.126].
Ferrara, F; Ventura, P; Vegetti, A; Guido, M; Abbati, G; Corradini, E; Fattovich, G; Ferrari, C; Tagliazucchi, M; Carbonieri, A; Orlandini, A; Fagiuoli, S; Boninsegna, S; Minola, E; Rizzo, G; Belussi, F; Felder, M; Massari, M; Pozzato, G; Bonetto, S; Rovere, P; Sardini, C; Borghi, A; Zeneroli, M; Toniutto, P; Rossi, E; Pietrangelo, A
File in questo prodotto:
File Dimensione Formato  
Ferrara AMJGAS.pdf

Solo gestori archivio

Dimensione 281.12 kB
Formato Adobe PDF
281.12 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/353641
Citazioni
  • Scopus 33
  • ???jsp.display-item.citation.isi??? 27
Social impact